Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Identification of cancer protein biomarkers using proteomic techniques

Patent ·
OSTI ID:1329309
The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.
Research Organization:
Yale University, New Haven, CT (United States)
Sponsoring Organization:
USDOE
Assignee:
Yale University (New Haven, CT
Patent Number(s):
9,470,688
Application Number:
14/602,916
OSTI ID:
1329309
Country of Publication:
United States
Language:
English

References (41)

Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions journal October 2004
Obesity, adipocytokines, and insulin resistance in breast cancer journal August 2004
Serum tumor markers in colorectal cancer staging, grading, and follow-up journal August 1996
The metastasis gene osteopontin: a candidate target for cancer therapy journal December 2001
Leptin expression in colorectal and breast cancer patients. journal April 2000
Leptin and prolactin modulate the expression of SOCS-1 in association with interleukin-6 and tumor necrosis factor-α in mammary cells: a role in differentiated secretory epithelium journal September 2004
Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer journal December 2003
Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine journal July 2004
Use of proteomic patterns in serum to identify ovarian cancer journal February 2002
Serum Vascular Endothelial Growth Factor and Serum Leptin in Patients with Cervical Cancer journal April 2002
Serum protein markers for early detection of ovarian cancer journal May 2005
Fasting Ghrelin Levels in Physically Active Women: Relationship with Menstrual Disturbances and Metabolic Hormones journal July 2004
Enhanced Expression of Leptin and Leptin Receptor (OB-R) in Human Breast Cancer journal July 2004
Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer journal April 2005
Expression of Leptin Receptors and Potential Effects of Leptin on the Cell Growth and Activation of Mitogen-Activated Protein Kinases in Ovarian Cancer Cells journal January 2005
Prolactin acts as a potent survival factor for human breast cancer cell lines journal June 2004
Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis journal May 2004
Diagnostic Markers for Early Detection of Ovarian Cancer journal February 2008
Leptin directly stimulates aromatase activity in human luteinized granulosa cells journal August 1999
Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients journal June 2004
Insulin-Like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions: Free IGF-II Is Correlated with Breast Cancer Size journal June 2004
No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery: Serum levels and breast cancer journal June 2004
Growth Factor Signaling Induces Metastasis Genes in Transformed Cells: Molecular Connection between Akt Kinase and Osteopontin in Breast Cancer journal August 2003
Multiplexed protein profiling on microarrays by rolling-circle amplification journal April 2002
Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer journal August 2004
Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer journal September 2004
The role of Osteopontin in tumor metastasis journal October 2004
Downregulation of long-form prolactin receptor mRNA during prolactin-induced luteal regression journal August 2000
Elevated Serum Insulin-Like Growth Factor Binding Protein-2 as a Prognostic Marker in Patients with Ovarian Cancer journal March 2004
Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer journal May 2004
Differential Gene Expression in Chemically Induced Mouse Lung Adenomas journal January 2003
Prolactin increases HO-1 expression and induces VEGF production in human macrophages journal January 2004
Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy journal September 1991
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma journal October 2004
Role of osteopontin in tumour progression journal April 2004
Multiple Kinase Cascades Mediate Prolactin Signals to Activating Protein-1 in Breast Cancer Cells journal December 2004
The Functional and Clinical Roles of Osteopontin in Cancer and Metastasis journal November 2001
Ovarian dysgerminoma showing high serum levels and positive immunostaining of placental alkaline phosphatase and neuron-specific enolase associated with elevation of serum prolactin level journal October 1998
Progress and Challenges in Screening for Early Detection of Ovarian Cancer journal February 2004
Cancer screening in a high risk population: a clinical trial journal April 2001
Prolactin as a tumour marker in cancer of the cervix journal January 1998